Did you know that CasInvent Pharma is one of the startups supported within CzechInvest’s Technological Incubation program? Through this program, we have received a grant of CZK 4.5 million, which allows us to accelerate both the chemical and biological development of our drug discovery projects.
With this funding, our team is currently working on the synthesis and optimization of ten novel drug candidates. In parallel, we are performing biological studies to evaluate their activity and efficacy in preclinical models. Together, these efforts are designed to provide a proof of concept that inhibitors targeting casein kinase 1 (CK1) could represent a promising therapeutic strategy in the treatment of melanoma.
Melanoma remains one of the most aggressive forms of skin cancer, with limited treatment options available once resistance to existing therapies develops. Exploring new molecular pathways is therefore an important step toward expanding the range of treatment possibilities for patients.
Although it is too early to share specific data, the first experimental results are very encouraging and provide a solid foundation for further development.
We greatly appreciate the support of CzechInvest, whose investment into innovative projects strengthens the Czech biotech ecosystem and enables young companies like CasInvent to bring new scientific approaches closer to clinical application.